|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2019. CA Cancer J Clin. 69:7–34. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Meister J and Schmidt MHH: miR-126 and
miR-126*: New players in cancer. ScientificWorldJournal.
10:2090–2100. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Fish JE, Santoro MM, Morton SU, Yu S, Yeh
RF, Wythe JD, Ivey KN, Bruneau BG, Stainier DY and Srivastava D:
miR-126 regulates angiogenic signaling and vascular integrity. Dev
Cell. 15:272–284. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Zhang Y, Yang P, Sun T, Li D, Xu X, Rui Y,
Li C, Chong M, Ibrahim T, Mercatali L, et al: miR-126 and
miR-126* repress recruitment of mesenchymal stem cells
and inflammatory monocytes to inhibit breast cancer metastasis. Nat
Cell Biol. 15:284–294. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ebrahimi F, Gopalan V, Smith RA and Lam
AK: miR-126 in human cancers: Clinical roles and current
perspectives. Exp Mol Pathol. 96:98–107. 2014. View Article : Google Scholar
|
|
6
|
Wang S, Aurora AB, Johnson BA, Qi X,
McAnally J, Hill JA, Richardson JA, Bassel-Duby R and Olson EN: The
endothelial-specific microRNA miR-126 governs vascular integrity
and angiogenesis. Dev Cell. 15:261–271. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lagos-Quintana M, Rauhut R, Yalcin A,
Meyer J, Lendeckel W and Tuschl T: Identification of
tissue-specific microRNAs from mouse. Curr Biol. 12:735–739. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Roviello G, Bachelot T, Hudis CA,
Curigliano G, Reynolds AR, Petrioli R and Generali D: The role of
bevacizumab in solid tumours: A literature based meta-analysis of
randomised trials. Eur J Cancer. 75:245–258. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Pan C, Stevic I, Müller V, Ni Q,
Oliveira-Ferrer L, Pantel K and Schwarzenbach H: Exosomal microRNAs
as tumor markers in epithelial ovarian cancer. Mol Oncol.
12:1935–1948. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Prahm KP, Høgdall C, Karlsen MA,
Christensen IJ, Novotny GW and Høgdall E: Identification and
validation of potential prognostic and predictive miRNAs of
epithelial ovarian cancer. PLoS One. 13:e02073192018. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wu G, Cao L, Zhu J, Tan Z, Tang M, Li Z,
Hu Y, Yu R, Zhang S, Song L, et al: Loss of RBMS3 confers platinum
resistance in epithelial ovarian cancer via activation of
miR-126-5p/ β-catenin/CBP signaling. Clin Cancer Res. 25:1022–1035.
2019. View Article : Google Scholar
|
|
12
|
Xiang G and Cheng Y: MiR-126-3p inhibits
ovarian cancer proliferation and invasion via targeting PLXNB2.
Reprod Biol. 18:218–224. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Luo P, Fei J, Zhou J and Zhang W:
microRNA-126 suppresses PAK4 expression in ovarian cancer SKOV3
cells. Oncol Lett. 9:2225–2229. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Cai J, Li T, Huang B, Cheng H, Ding H,
Dong W, Xiao M, Liu L and Wang Z: The use of laser microdissection
in the identification of suitable reference genes for normalization
of quantitative real-time PCR in human FFPE epithelial ovarian
tissue samples. PLoS One. 9:e959742014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Xie H, Zou L, Zhu J and Yang Y: Effects of
netrin-1 and netrin-1 knockdown on human umbilical vein endothelial
cells and angio-genesis of rat placenta. Placenta. 32:546–553.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
17
|
Li Q, Cheng K, Wang AY, Xu QG, Fu ZF, He
SY and Xu PX: microRNA-126 inhibits tube formation of HUVECs by
interacting with EGFL7 and down-regulating PI3K/AKT signaling
pathway. Biomed Pharmacother. 116:1090072019. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Guo J, Cai J, Yu L, Tang H, Chen C and
Wang Z: EZH2 regulates expression of p57 and contributes to
progression of ovarian cancer in vitro and in vivo. Cancer Sci.
102:530–539. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Bu J, Li H, Li XY, Liu LH, Sun W and Xiao
T: Prognostic role of microRNA-126 for survival in malignant
tumors: A systematic review and meta-analysis. Dis Markers.
2015:7394692015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Gu L, Li H, Chen L, Ma X, Gao Y, Li X,
Zhang Y, Fan Y and Zhang X: MicroRNAs as prognostic molecular
signatures in renal cell carcinoma: A systematic review and
meta-analysis. Oncotarget. 6:32545–32560. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Luo J, Zhu C, Wang H, Yu L and Zhou J:
MicroRNA-126 affects ovarian cancer cell differentiation and
invasion by modulating expression of vascular endothelial growth
factor. Oncol Lett. 15:5803–5808. 2018.PubMed/NCBI
|
|
22
|
Chen H, Li L, Wang S, Lei Y, Ge Q, Lv N,
Zhou X and Chen C: Reduced miR-126 expression facilitates
angiogenesis of gastric cancer through its regulation on VEGF-A.
Oncotarget. 5:11873–11885. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Chen CY, Su CM, Hsu CJ, Huang CC, Wang SW,
Liu SC, Chen WC, Fuh LJ and Tang CH: CCN1 promotes VEGF production
in osteoblasts and induces endothelial progenitor cell angiogenesis
by inhibiting miR-126 expression in rheumatoid arthritis. J Bone
Miner Res. 32:34–45. 2017. View Article : Google Scholar
|
|
24
|
Kong D, Ying B, Zhang J and Ying H: The
anti-osteosarcoma property of ailanthone through regulation of
miR-126/VEGF-A axis. Artif Cells Nanomed Biotechnol. 47:3913–3919.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Liu B, Peng XC, Zheng XL, Wang J and Qin
YW: MiR-126 restoration down-regulate VEGF and inhibit the growth
of lung cancer cell lines in vitro and in vivo. Lung Cancer.
66:169–175. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Caporali S, Amaro A, Levati L, Alvino E,
Lacal PM, Mastroeni S, Ruffini F, Bonmassar L, Antonini Cappellini
GC, Felli N, et al: miR-126-3p down-regulation contributes to
dabrafenib acquired resistance in melanoma by up-regulating ADAM9
and VEGF-A. J Exp Clin Cancer Res. 38:2722019. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Cortez AJ, Tudrej P, Kujawa KA and
Lisowska KM: Advances in ovarian cancer therapy. Cancer Chemother
Pharmacol. 81:17–38. 2018. View Article : Google Scholar :
|
|
28
|
Pujade-Lauraine E, Hilpert F, Weber B,
Reuss A, Poveda A, Kristensen G, Sorio R, Vergote I, Witteveen P,
Bamias A, et al: Bevacizumab combined with chemotherapy for
platinum-resistant recurrent ovarian cancer: The AURELIA open-label
randomized phase III trial. J Clin Oncol. 32:1302–1308. 2014.
View Article : Google Scholar : PubMed/NCBI
|
